Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898404 | 1.00 | CASP3 (0.41) | CASP3SENP7SENP6CHRM2CHRM4 | |
| SCHEMBL4082606 | 0.85 | RAB9A (0.47) | CASP3SENP7SENP6NR1H4 | |
| SCHEMBL16464581 | 0.85 | RAB9A (0.47) | CASP3SENP7SENP6NR1H4 | |
| SCHEMBL3975733 | 0.85 | RAB9A (0.47) | CASP3SENP7SENP6NR1H4 | |
| SCHEMBL8226952 | 0.85 | NR1H4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2899343 | 0.85 | RPS6KB1 (0.42) | HTR7NR1H4NISCHGRM5 | |
| SCHEMBL2899344 | 0.85 | RPS6KB1 (0.42) | HTR7NR1H4NISCHGRM5 | |
| SCHEMBL5483346 | 0.85 | RAB9A (0.48) | HTR7NR1H4 | |
| SCHEMBL14387422 | 0.85 | NR1H4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL17063997 | 0.84 | RAB9A (0.46) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | CASP3 4334/4885SENP7 3465/4885SENP6 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.